These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 34391504)

  • 1. Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients.
    Carr EJ; Wu M; Harvey R; Wall EC; Kelly G; Hussain S; Howell M; Kassiotis G; Swanton C; Gandhi S; Bauer DL; ; ; Billany RE; Graham-Brown MP; Beckett J; Bull K; Shankar S; Henderson S; Motallebzadeh R; Salama AD; Harper L; Mark PB; McAdoo S; Willicombe M; Beale R
    Lancet; 2021 Sep; 398(10305):1038-1041. PubMed ID: 34391504
    [No Abstract]   [Full Text] [Related]  

  • 2. Humoral response to SARS-CoV-2 vaccination in haemodialysis patients and a matched cohort.
    Zhao T; Nishi-Uchi T; Omata F; Takita M; Kawashima M; Nishikawa Y; Yamamoto C; Kobashi Y; Kawamura T; Shibuya K; Kazama J; Shineha R; Tsubokura M
    BMJ Open; 2022 Nov; 12(11):e065741. PubMed ID: 36351730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients.
    Carr EJ; Wu M; Harvey R; Billany RE; Wall EC; Kelly G; ; Howell M; Kassiotis G; Swanton C; Gandhi S; Bauer DL; Graham-Brown MP; Jones RB; Smith RM; McAdoo S; Willicombe M; Beale R
    Lancet; 2022 Feb; 399(10327):800-802. PubMed ID: 35065703
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
    Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
    Front Immunol; 2021; 12():690698. PubMed ID: 34276681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humoral response after SARS-CoV-2 vaccination in patients undergoing maintenance haemodialysis: loss of immunity, third dose and non-responders.
    Robert T; Lano G; Giot M; Fourié T; de Lamballeri X; Jehel O; Bouchouareb D; Brunet P; Ninove L; Burtey S
    Nephrol Dial Transplant; 2022 Jan; 37(2):390-392. PubMed ID: 34643714
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time-dependent evolution of IgG antibody levels after first and second dose of mRNA-based SARS-CoV-2 vaccination in haemodialysis patients: a multicentre study.
    Santos-Araújo C; Mota Veiga P; Santos MJ; Santos L; Romãozinho C; Silva M; Lucas C; Duarte ML; Haarhaus M; Haase M; Macário F
    Nephrol Dial Transplant; 2022 Jan; 37(2):375-381. PubMed ID: 34634116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 infection long time after full vaccination is related to a lack of neutralizing antibodies.
    Alidjinou EK; Gaillot O; Guigon A; Tinez C; Lazrek M; Bocket L; Engelmann I; Hober D
    Diagn Microbiol Infect Dis; 2022 Jan; 102(1):115565. PubMed ID: 34731684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measuring cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine (BNT126b2) in patients on maintenance haemodialysis.
    Martin P; Clarke C
    EBioMedicine; 2021 Sep; 71():103567. PubMed ID: 34454401
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
    Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
    Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralizing SARS-CoV-2 antibody response in dialysis patients after the first dose of the BNT162b2 mRNA COVID-19 vaccine: the war is far from being won.
    Torreggiani M; Blanchi S; Fois A; Fessi H; Piccoli GB
    Kidney Int; 2021 Jun; 99(6):1494-1496. PubMed ID: 33887320
    [No Abstract]   [Full Text] [Related]  

  • 12. COVID-19 vaccination and BA.1 breakthrough infection induce neutralising antibodies which are less efficient against BA.4 and BA.5 Omicron variants, Israel, March to June 2022.
    Kliker L; Zuckerman N; Atari N; Barda N; Gilboa M; Nemet I; Abd Elkader B; Fratty IS; Jaber H; Mendelson E; Alroy-Preis S; Kreiss Y; Regev-Yochay G; Mandelboim M
    Euro Surveill; 2022 Jul; 27(30):. PubMed ID: 35904058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial.
    Lazarus R; Querton B; Corbic Ramljak I; Dewasthaly S; Jaramillo JC; Dubischar K; Krammer M; Weisova P; Hochreiter R; Eder-Lingelbach S; Taucher C; Finn A;
    Lancet Infect Dis; 2022 Dec; 22(12):1716-1727. PubMed ID: 36075233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing antibody responses 300 days after SARS-CoV-2 infection and induction of high antibody titers after vaccination.
    Urlaub D; Wolfsdorff N; Hoffmann JE; Dorok S; Hoffmann M; Anft M; Pieris N; Günther P; Schaaf B; Cassens U; Bröde P; Claus M; Picard LK; Wingert S; Backes S; Durak D; Babel N; Pöhlmann S; Renken F; Raunser S; Watzl C
    Eur J Immunol; 2022 May; 52(5):810-815. PubMed ID: 35247269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network.
    Neuhann JM; Stemler J; Carcas A; Frías-Iniesta J; Bethe U; Heringer S; Tischmann L; Zarrouk M; Cüppers A; König F; Posch M; Cornely OA
    Trials; 2022 Oct; 23(1):865. PubMed ID: 36209129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Robust induction of neutralizing antibodies against the SARS-CoV-2 Delta variant after homologous Spikevax or heterologous Vaxzevria-Spikevax vaccination.
    Hammerschmidt SI; Thurm C; Bošnjak B; Bernhardt G; Reinhold A; Willenzon S; Ritter C; Reinhold D; Schraven B; Förster R
    Eur J Immunol; 2022 Feb; 52(2):356-359. PubMed ID: 34870322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
    Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
    Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
    Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
    Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 mRNA vaccination is not associated with the induction of anti-HLA or non-HLA antibodies.
    Wijtvliet VPWM; Verheyden S; Depreter B; Heylen C; Coeman E; Abrams S; De Winter BY; Massart A; Hellemans R; Pipeleers L; Claas FHJ; Ariën KK; Wissing KM; Abramowicz D; Ledeganck KJ
    Transpl Immunol; 2022 Oct; 74():101670. PubMed ID: 35835296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody maintenance 3 months after complete messenger RNA COVID-19 vaccination in haemodialysis patients.
    Broseta JJ; Rodríguez-Espinosa D; Bedini JL; Rodríguez N; Maduell F
    Nephrol Dial Transplant; 2021 Dec; 36(12):2340-2341. PubMed ID: 34534347
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 26.